Qiagen won Chinese regulatory approval for a next-generation tuberculosis test and expects a commercial rollout there in the early part of 2014.
With the success of Erbitux and its patient-steering companion diagnostic fresh in mind, Qiagen and Eli Lilly have struck up their third partnership, reuniting to match genomic knowhow with drug development expertise.
Biotech Clovis Oncology is tapping Qiagen's diagnostic expertise as it develops an EGFR-targeting lung cancer treatment, tasking the German company with creating a companion test that can identify patients for clinical trials and, eventually, be sold alongside the drug.
Qiagen plans to move ahead with a $100 million share repurchase program in the wake of improved revenue and sales in the 2013 second quarter on nearly all fronts.
Qiagen's string of companion diagnostics success continues with the FDA's approval of a molecular test for lung cancer, OK'd alongside a targeted Boehringer Ingelheim drug.
Qiagen has licensed a few a cancer biomarkers the company said will help expand its heft in the lucrative companion diagnostics world, targeting gene expressions that jibe with in-development therapies.
Roche's surging diagnostics arm scored a major win this week, gaining FDA approval what is being billed as the first companion diagnostic meant to detect a specific mutation connected to metastatic non-small cell lung cancer.
Qiagen has purchased Ingenuity Systems for $105 million in cash. The Netherlands-based buyer plans to integrate the genomic database and analysis software from Ingenuity into its molecular diagnostics business. The buyout highlights the growing value of understanding the nuances of genomics to make precise diagnoses.
Dutch diagnostics giant Qiagen grabbed Ingenuity Systems in a $105 million cash deal, giving it new technology to boost the analysis of genomic data for molecular diagnostics.
Eli Lilly is expanding its partnership with Qiagen, building off of past success in a new broad collaboration agreement for companion diagnostics.